Quipt Home Medical price target lowered to $7 from $9 at Benchmark

Benchmark lowered the firm’s price target on Quipt Home Medical to $7 from $9 and keeps a Buy rating on the shares. In fiscal Q3, sequential revenue growth improved to flattish, though shy of consensus, notes the firm, which now “conservatively” models sequentially flat revenue for fiscal Q4, down from a 1.5% prior growth forecast. For FY25, Benchmark believes Quipt can return to management’s long-term 8%-10% organic growth target, the analyst noted.